ESMO Breast 2025 | Key challenges in integrating AI into breast cancer screening

Kristina Lang • 15 May 2025

ESMO Breast 2025

Breast Cancer

MASAI

Kristina Lang, MD, PhD, Lund University, Malmö, Sweden, outlines current challenges in integrating artificial intelligence (AI) into breast cancer screening. While the MASAI trial (NCT04838756) highlights the potential of AI in enhancing diagnostic accuracy, key issues remain—such as the need to confirm primary endpoints, evaluate long-term effectiveness, and establish cost-effectiveness. She also raises questions about maintaining clinical judgment as the use of AI grows, emphasizing the importance of ongoing validation, quality monitoring, and careful implementation in real-world settings. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.